Drug Database
RE

recombinant human interferon alfa-2a

✓ Approved

BioGeneric Pharma · IFNAR2 · 重组蛋白

什么是 recombinant human interferon alfa-2a?

recombinant human interferon alfa-2a 是一种重组蛋白,由BioGeneric Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

公司BioGeneric Pharma
药物类别重组蛋白
分子靶点IFNAR2
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

recombinant human interferon alfa-2a 作用于 1 个分子靶点:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

recombinant human interferon alfa-2a 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsHepatitis C✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasm malignant✓ Approved

相关研究文献

PubMedFrontiers in reproductive health2026-11-18

Follitropin alfa versus follitropin alfa/lutropin alfa (rFSH/rLH) in progestin-primed ovarian stimulation: a prospective two-center observational cohort study.

Pabuccu Emre E, Tohma Yusuf Aytac YA, Ozkavukcu Sinan S

The contribution of recombinant LH during progestin-primed ovarian stimulation (PPOS) remains uncertain. We compared recombinant FSH alone (GON) with recombinant FSH plus recombinant LH (PER) in a prospective two-center observational cohort. The full enrolled cohort included 213 women (121 GON; 92 PER), including 11 with day-3 transfer. MII oocyte count was the primary outcome. The primary negative binomial model adjusted for female age, AMH, baseline AFC, previous failed cycles and center. Propensity scores used the same covariates; matching was 1:1, exact within center, using Mahalanobis distance within a logit propensity-score caliper. The per-protocol (PP) population comprised the 202 women whose embryos were cultured to day 5; in the full-cohort (ITT) analysis, the 11 women with day-3 transfer contributed zero day-5 blastocysts. The primary adjusted MII incidence rate ratio (IRR) for PER versus GON was 1.01 (95% CI 0.91-1.11; p = 0.910); the PP IRR was 1.00 (95% CI 0.91-1.11; p = 0.939). The number of MII oocytes was similar in both groups (median 11 in both), and this finding did not change after adjustment for baseline characteristics or after propensity-score matching. PER was associated with more day-5 blastocysts (median 4 vs. 3) and more top-quality blastocysts (median 2 vs. 1), and these differences persisted after adjustment and matching. Positive β-hCG rates after the first frozen embryo transfer were similar (47.6% vs. 43.2%). OHSS was rare (1 PER and 2 GON cases, all mild), and no cycle was canceled. No statistically significant difference in MII count was detected, and equivalence was not established. The higher day-5 blastocyst counts associated with PER may reflect an effect of LH on embryo developmental competence rather than on oocyte yield; this exploratory finding does not establish a causal or clinical benefit and requires confirmation in randomized trials. https://clinicaltrials.gov/study/NCT07348757, NCT07348757.

PMID 43047481
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Recombinant Human Collagen in Clinical Medicine.

Yi Kyu-Ho KH, Song Jong Keun JK, Kim Hongseok H

Collagen is the dominant structural protein of vertebrate connective tissues and a central biomaterial in skin, cornea, tendon, cartilage, bone, vessel, oral mucosa, and wound repair. Traditional collagen products have largely been extracted from bovine, porcine, fish, or other animal tissues. Although animal-derived collagens have a long clinical history, they have limitations including batch variability, residual nonhuman epitopes, possible immunogenicity, pathogen-related concerns, ethical constraints, and limited molecular engineering. Recombinant human collagen has emerged as a synthetic-biology alternative designed to reproduce full-length human collagen chains, selected human collagen domains, or engineered humanized collagen-like sequences in controlled expression systems. This systematic review and narrative synthesis summarizes the biological basis, production methods, molecular types, benefits, clinical applications, aesthetic uses, safety considerations, and translational limitations of recombinant human collagen, with emphasis on dermatology, wound healing, corneal regeneration, tissue engineering, injectable aesthetics, and dermal rejuvenation. A PRISMA-informed systematic search was performed across biomedical databases, publisher platforms, and regulatory sources for literature on recombinant human collagen, recombinant humanized collagen, recombinant type I collagen, recombinant type III collagen, recombinant collagen hydrogels, collagen-based medical devices, dermal fillers, wound healing, corneal substitutes, tissue engineering, photoaging repair, and aesthetic applications. Because the evidence base includes heterogeneous manufacturing papers, in vitro studies, animal experiments, early clinical trials, case series, and regulatory documents, quantitative meta-analysis was not performed. Recombinant human collagen offers human-sequence design, reduced animal-origin risk, improved batch consistency, scalable manufacturing potential, and engineering flexibility. Type I and type III recombinant collagens are most relevant to dermal, wound, tendon, corneal, and aesthetic applications, whereas type IV, VII, and XVII collagens are increasingly relevant to basement membrane and epidermal adhesion biology. Production remains technically demanding because native collagen requires triple-helix formation and post-translational modifications such as proline hydroxylation. Current strategies include yeast expression with prolyl-4-hydroxylase co-expression, microbial production of collagen-like fragments, mammalian and insect cell systems, transgenic plants, chemical modification, cross-linked microgels, and collagen-based bioinks. Recombinant human collagen is a platform biomaterial rather than a single product class. Its clinical value depends on matching collagen type, molecular format, formulation, degradation profile, mechanical behavior, and biological indication. In aesthetic medicine, its strongest future role may be regenerative matrix restoration rather than simple volume replacement. Larger randomized trials, long-term safety surveillance, and standardized quality-control methods are required before broad equivalence with established animal collagens, hyaluronic acid fillers, or biostimulatory injectables can be assumed.

PMID 43047109
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Microneedle-Assisted Delivery of PEGylated Recombinant Human Fusion Collagen for Androgenetic Alopecia: Preclinical and Pilot Clinical Evidence.

Jin Meitong M, Kong Yanli Y, Ge Ling L, Luo Yinli Y et al.

Androgenetic alopecia (AGA), the most common form of progressive hair loss in men, significantly impairs both physical and psychological well-being. While traditional research has predominantly focused on cellular components and signaling pathways, the extracellular matrix (ECM)-particularly collagen-is increasingly recognized as playing a dual role: serving as both a structural scaffold and a dynamic signaling reservoir for hair follicles. Consequently, a recombinant fusion collagen that integrates key functional domains of human types III and XVII collagen with hair follicle-targeting sequences represents a promising strategy for ECM replenishment and functional restoration. This study aimed to evaluate the therapeutic feasibility and underlying mechanisms of microneedle-assisted delivery of PEGylated recombinant human fusion collagen (PEG-rhCol-F) for AGA treatment. The therapeutic efficacy of microneedle-delivered PEG-rhCol-F was first evaluated in a testosterone-induced AGA mouse model through morphological, histological, and molecular analyzes (Western blotting). Subsequently, a three-month pilot clinical trial involving 15 AGA patients was conducted. Patients received microneedling combined with a PEG-rhCol-F liquid dressing, and treatment outcomes were assessed via trichoscopy. In the AGA mouse model, PEG-rhCol-F treatment significantly promoted hair regrowth, increased hair follicle count, and facilitated the transition to the anagen phase. Mechanistically, this was associated with the activation of the Wnt/β-catenin-VEGF axis. Correspondingly, the clinical trial demonstrated a marked improvement in hair density and diameter from baseline, along with a shift from vellus to terminal hairs. The treatment regimen was well-tolerated, with only mild, transient adverse reactions (e.g., erythema) observed. This pilot study provides initial evidence for the efficacy and safety of microneedle-assisted PEG-rhCol-F delivery for AGA patients. By combining structural ECM repair with functional pathway activation, this dual-mechanism approach merits further clinical investigation.

PMID 43046962
阅读全文 →
PubMedFrontiers in pharmacology2026-11-18

Lidocaine modulates interleukin-1β and interferon-α2 secretion in LPS with ATP stimulated human peripheral blood mononuclear cells.

Oostwouder Cees-Jan CJ, Vos Karin K, Merkus Mathijs R MR, Tolsma Casper S CS et al.

Local anesthetics are canonically used for analgesia and anti-arrhythmic therapy, but increasing evidence indicates additional anti-inflammatory properties, including modulation of purinergic signalling. A recent retrospective observational cohort study indicated that subcutaneous lidocaine-Hydroxypropyl-β-cyclodextrin (HP-β-CD) was associated with sustained improvements in quality of life in patients with neuropathic pain in post-COVID, but the underlying mechanism remains to be established. The aim of this study was to determine whether lidocaine and articaine, alone or in combination with HP-β-CD, modulate in vitro immune cell activation and cytokine secretion in human peripheral blood mononuclear cells (PBMCs). PBMCs were stimulated using phytohemagglutinin (PHA), lipopolysaccharide (LPS), or LPS combined with adenosine triphosphate (ATP) to engage P2X-associated inflammatory pathways, and compounds were applied both prior to and following stimulation. Cytokine secretion was quantified using a 13-plex immunoassay and cell activation was assessed by flow cytometry. Lidocaine-containing formulations attenuated cytokine secretion most prominently under conditions engaging ATP-dependent signaling, reducing interleukin-1β and interferon-α2, with interleukin-1β suppression being the most consistent effect across stimulation conditions. Articaine showed less consistent immunomodulatory effects than lidocaine, which may reflect its previously reported lack of purinergic receptor inhibition, while HP-β-CD alone did not influence immune activation or cytokine release under any condition. Together, these findings show that lidocaine-containing treatments can modulate cytokine responses in human PBMCs, particularly under LPS with ATP stimulation. These findings identify lidocaine as a modulator of ATP-dependent inflammatory signaling.

PMID 43047804
阅读全文 →
PubMedCommunications biology2026-11-18

The DR-DQ HLA haplotypes dominant-recessive interplay leads to the heterogeneity of antibody immune response in T1D.

Telnaya Elizaveta A EA, Petriaikina Ekaterina S ES, Antysheva Zoia G ZG, Tychinin Dmitry I DI et al.

Type 1 diabetes mellitus (T1D) is an autoimmune disorder defined by the presence of islet-specific autoantibodies (AAb). Growing evidence indicates substantial heterogeneity in T1D pathogenesis, reflected in divergent AAb profiles across patient subgroups. We integrated ELISA-based measurements of four major islet autoantibodies-insulin (IAA), glutamic acid decarboxylase (GADA), IA-2 (IA-2A), and zinc transporter 8 (ZnT8A)-with whole-genome sequencing (WGS) data from 917 individuals diagnosed with T1D or latent autoimmune diabetes in adults (LADA). Analyses were stratified by class II human leukocyte antigen (HLA) haplotypes, age at disease onset (0-55 years old), sex, and disease duration (0-51 years). To investigate seroconversion dynamics during the preclinical phase, we additionally included 72 preclinical participants. HLA haplotype emerged as the primary determinant of AAb specificity, while dominant-recessive interactions between alleles in the heterozygous state have been revealed. In addition to confirming the previously described associations between IA-2A and ZnT8A with DR4-DQ8 and GADA with DR3-DQ2, an increase in ZnT8A levels was detected for heterozygotes of the DR1-DQ5 haplotype. Moreover, even within identical HLA backgrounds, sex, age at onset, and disease duration significantly modulated the autoantibody repertoire. These findings demonstrate that HLA haplotype is a major driver of T1D heterogeneity, while non-HLA factors may modify its effects. The observed immunological heterogeneity underscores the need for multidimensional stratification in T1D research and highlights opportunities for HLA-informed prediction and monitoring during the preclinical window.

PMID 43045777
阅读全文 →
PubMedTherapeutic advances in hematology2026-11-18

Real-world effectiveness and usage of rFIXFc prophylaxis in hemophilia B: Final results from the B-MORE study.

Glosli Heidi H, Al Saleh Mahasen M, Nolan Beatrice B, Allsup David D et al.

Eftrenonacog alfa is an extended half-life recombinant factor IX Fc fusion protein (rFIXFc) approved for the treatment and prevention of bleeding episodes in people with hemophilia B (PwHB). Providing continuous and comprehensive real-world data is crucial to support informed treatment strategies with rFIXFc in routine practice. The B-MORE study was designed to provide further insights into real-world utilization and effectiveness of rFIXFc in PwHB. To describe the final real-world effectiveness and usage data for rFIXFc in PwHB from B-MORE. B-MORE (NCT03901755) was a 24-month prospective, non-interventional study across Europe and the Middle East. Eligible patients had hemophilia B and started rFIXFc treatment before or at enrollment, regardless of study participation. Descriptive analyses were performed for patients who received ≥6 months of rFIXFc prophylaxis, either during the prospective period or since rFIXFc initiation (before/at enrollment). Additionally, intrapatient comparisons with prior standard half-life (SHL) FIX prophylaxis were conducted. Endpoints included annualized bleeding rate (ABR), injection frequency, factor consumption, and treatment satisfaction. B-MORE enrolled 151 patients from 29 centers; >80% completed the study. In the prospective period (N=137), median (interquartile range)/mean ABR was low at 0.5 (0.0-1.2)/0.9. Median (interquartile range) injection frequency and factor consumption were also low with 52.5 (52.2-52.6) injections/year and 2,443 (2,022-2,970) IU/kg/year, respectively. Results were similar since rFIXFc initiation (N=137). Compared to prior SHL prophylaxis (N=92), ABR was reduced/remained low, while injection frequency and factor consumption reduced since rFIXFc initiation. Most physicians (88.5%; 69/78) and patients (90.0%; 90/100) were satisfied/highly satisfied with rFIXFc prophylaxis. B-MORE represents the largest real-world investigation of rFIXFc usage, with up to nearly seven years of follow-up (retrospective and prospective periods). Final data confirm rFIXFc as an effective and well-tolerated long-term prophylactic treatment for hemophilia B.

PMID 43047976
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多recombinant human interferon alfa-2a